Perrone, E.; Giordano, A.; Calcagni, M.L.; Leccisotti, L.; Moretti, R.; Eismant, A.; Ghai, K.; Parkar, T.; Mishra, A.; Heidenreich, A.;
et al. Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer. Cancers 2025, 17, 405.
https://doi.org/10.3390/cancers17030405
AMA Style
Perrone E, Giordano A, Calcagni ML, Leccisotti L, Moretti R, Eismant A, Ghai K, Parkar T, Mishra A, Heidenreich A,
et al. Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer. Cancers. 2025; 17(3):405.
https://doi.org/10.3390/cancers17030405
Chicago/Turabian Style
Perrone, Elisabetta, Alessandro Giordano, Maria Lucia Calcagni, Lucia Leccisotti, Roberto Moretti, Aleksandr Eismant, Kriti Ghai, Tanay Parkar, Aditi Mishra, Axel Heidenreich,
and et al. 2025. "Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer" Cancers 17, no. 3: 405.
https://doi.org/10.3390/cancers17030405
APA Style
Perrone, E., Giordano, A., Calcagni, M. L., Leccisotti, L., Moretti, R., Eismant, A., Ghai, K., Parkar, T., Mishra, A., Heidenreich, A., Wirtz, R. M., Müller, J., Greifenstein, L., & Baum, R. P.
(2025). Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer. Cancers, 17(3), 405.
https://doi.org/10.3390/cancers17030405
